

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-63 (canceled)

Claim 64 (currently amended): A method for increasing antigen-specific IgE production comprising administering to ~~an animal~~ a patient a therapeutically effective amount of a polypeptide comprising SEQ ID NO 2 or SEQ ID NO 5.

Claims 65 (currently amended): A method for increasing antigen -specific IgE production comprising administering to ~~an animal~~ a patient a therapeutically effective amount of a polypeptide encoded by a nucleic acid sequence comprising SEQ ID NO 1, 2 or 4.

Claim 66 (previously presented): A method for detecting antigen-specific IgE production comprising contacting a sample with an antibody or fragment thereof which specifically binds a polypeptide selected from the group consisting of a) a polypeptide comprising the amino acid sequence of SEQ ID NO. 2 or SEQ ID NO. 5; or b) a polypeptide encoded by a nucleic acid sequence comprising SEQ ID NO 1, 2 or 4.

Claims 67-80 (canceled)

Claim 81 (new): A method for the treatment of an IgE-related disease comprising administering to a patient a therapeutically effective amount of an isolated and purified antibody or fragment thereof that specifically binds a polypeptide selected from the group consisting of a) a polypeptide comprising SEQ ID NO. 2 or SEQ ID NO. 5; or b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NO. 1, 3, or 4.

Claim 82 (new): The method of claim 81 wherein the antibody comprises a monoclonal antibody.

Claim 83 (new): The method of claim 81 wherein the antibody comprises a humanized antibody.

Claim 84 (new): The method of claim 81 wherein the antibody comprises a fully human antibody.

Claim 85 (new): The method of claim 81 wherein the antibody comprises a polyclonal antibody.

Claim 86 (new): The method of claim 81 wherein the antibody comprises a chimeric antibody.

Claim 87 (new): The method of claim 81 wherein the antibody comprises a CDR-grafted antibody.

Claim 88 (new): The method of claim 81 wherein the antibody comprises a bi-specific antibody.

Claim 89 (new): The method of claim 81 wherein the antibody comprises a single chain antibody.

Claim 90 (new): The method of claim 81 wherein the antibody comprises a variable region.

Claim 91 (new): The method of claim 81 wherein the antibody comprises an Fab.

Claim 92 (new): The method of claim 81 wherein the antibody comprises a Fab' fragment.

Claim 93 (new): The method of claim 81 wherein the antibody comprises an Fc fragment.

Claim 94 (new): The method of claim 81 wherein the antibody is bound to a detectable label.

Claim 95 (new): The method of claim 81 wherein the antibody is produced from a hybridoma.